EX-5.1 3 a19-2950_1ex5d1.htm EX-5.1

Exhibit 5.1



90 Park Avenue

New York, NY  10016

212-210-9400 | Fax: 212-210-9444


Matthew W. Mamak

Direct Dial: 212-210-1256

Email: matthew.mamak@alston.com


January 15, 2019


Stemline Therapeutics, Inc.

750 Lexington Avenue, 11th Floor

New York, New York 10022


Re:                        Stemline Therapeutics, Inc. — Public Offering of Shares of Common Stock


Ladies and Gentlemen:


We are acting as counsel to Stemline Therapeutics, Inc., a Delaware corporation (the “Company”) in connection with the registration statement on Form S-3 (File No. 333-219794) filed by the Company with the Securities and Exchange Commission (the “Commission”) pursuant to the Securities Act of 1933, as amended (the “Securities Act”), on August 8, 2017 (the “Registration Statement”) and declared effective by the Commission on August 18, 2017, and the issuance and sale of an aggregate of 10,222,222 shares (the “Shares”) of common stock, par value $0.0001 per share, of the Company (the “Common Stock”), which includes 1,333,333 Shares issuable upon the exercise of an option to purchase additional shares granted by the Company to the Underwriters. The Company is selling the Shares to J.P. Morgan Securities LLC (the “Underwriter”) pursuant to the Underwriting Agreement dated January 15, 2019 (the “Underwriting Agreement”) between the Company and the Underwriter. This opinion is being furnished to you at your request in accordance with the requirements of Item 16 of the Commission’s Form S-3 and Item 601(b)(5) of Regulation S-K promulgated under the Securities Act.


We have examined the Amended and Restated Certificate of Incorporation of the Company, the Restated Bylaws of the Company, records of proceedings of the Board of Directors, or committees thereof, and records of proceedings of the stockholders, deemed by us to be relevant to this opinion letter, and the Registration Statement.  We also have made such further legal and factual examinations and investigations as we deemed necessary for purposes of expressing the opinion set forth herein.  In rendering such opinion, we have relied as to factual matters upon the representations, warranties and other statements made in the Underwriting Agreement.


As to certain factual matters relevant to this opinion letter, we have relied conclusively upon originals or copies, certified or otherwise identified to our satisfaction, of such records, agreements, documents and instruments, including certificates or other comparable documents of officers of the Company and of public officials, as we have deemed appropriate as a basis for


Alston & Bird LLP



Atlanta | Beijing | Brussels | Charlotte | Dallas | Los Angeles | New York | Research Triangle | San Francisco | Silicon Valley | Washington, D.C.



the opinion hereinafter set forth.  Except to the extent expressly set forth herein, we have made no independent investigations with regard to matters of fact, and, accordingly, we do not express any opinion as to matters that might have been disclosed by independent verification.


Based upon the foregoing and subject to the limitations, qualifications, exceptions and assumptions set forth herein, we are of the opinion that the Shares have been duly authorized by all necessary corporate action of the Company and are validly issued, fully paid and nonassessable.


Our opinion set forth herein is limited to the General Corporation Law of the State of Delaware, the laws of the State of New York, and the federal law of the United States, and we do not express any opinion herein concerning any other laws.


This opinion letter is provided to the Company for its use solely in connection with the transactions contemplated by the Underwriting Agreement and may not be used, circulated, quoted or otherwise relied upon for any other purpose without our express written consent.  The only opinion rendered by us consists of that set forth in the fourth paragraph of this letter, and no opinion may be implied or inferred beyond the opinion expressly stated.  Our opinion expressed herein is as of the date hereof, and we undertake no obligation to advise you of any changes in applicable law or any other matters that may come to our attention after the date hereof that may affect our opinion expressed herein.


We consent to the filing of this opinion letter as an exhibit to a Current Report on Form 8-K to be incorporated by reference into the Registration Statement and to the use of our name under the heading “Legal Matters” in the prospectus supplement dated January 15, 2019 filed together with the prospectus dated August 18, 2017 by the Company with the Commission pursuant to Rule 424(b)(5) under the Securities Act on August 8, 2017.  In giving such consent, we do not thereby admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act, or the rules and regulations of the Commission thereunder.



Very truly yours,









/s/ Matthew W. Mamak



Matthew W. Mamak